Primary adrenocortical carcinoma: a case report
Durga Neupane, MBBSª, Sarada Khadka, MCHb ;* , Paricha Upadhyaya, MDº, Suresh P. Sah, MSª, Soniya Dulal, MSd, Siddhartha K. Shah, MBBSª, Ujjwal K. Shah, MBBSª
Introduction: Adrenal tumors are very common, affecting 3-10% of the human population, and most are small, benign, nonfunctional adrenocortical adenomas. Adrenocortical carcinoma (ACC), in contrast, is a very rare disease. The median age of diagnosis is in the fifth to sixth decade. There is a predilection for the female gender (the ratio of female to male ranges from 1.5 to 2.5 : 1) the adult.
Case presentation: A 28-year-old man who had no prior history of systemic hypertension or diabetes mellitus presented with bilateral limb swelling for 2 months and facial puffiness for 1 month. He had an episode of hypertensive emergencies. A radiological and hormonal work-up established the diagnosis of primary ACC. One cycle of chemotherapy was given until he lost follow-up and succumbed to death due to financial constraints.
Conclusions: Adrenocortical carcinoma is an extremely uncommon tumor of the adrenal gland, and it is even more uncommon when it manifests without any symptoms. If patients exhibit signs of rapid and multiple adrenocortical hormone excess, such as weakness, hypokalaemia, or hypertension, ACC may be suspected. Recently developed gynecomastia in men may be brought on by an ACC producing too much sex hormone. To accurately diagnose the condition and give the patient a fair prognosis, a multidisciplinary approach involving endocrine surgeons, oncologists, radiologists, and internists is advised. Proper genetic counseling is recommended. It is critical to know whether the adrenal mass is malignant or not, and to get this ascertained by a computed tomography finding and biopsy.
Keywords: case report, primary adrenocortical carcinoma, chemotherapy, tumor
Introduction
Adrenal tumors, affecting 3-10% of the human population, are very common, and most are small, benign, nonfunctional adre- nocortical adenomas[1]. Adrenocortical carcinoma (ACC), how- ever, is a very rare disease. The National Institutes of Health Office of Rare Diseases Research defines rare diseases as having a prevalence of fewer than 200 000 patients in the United States[2]. In accordance with the aforementioned definition, ACC might be regarded as an ultrarare disease. The incidence is believed to be 1-2 per million per year; however, valid data are lacking[3]. The Surveillance, Epidemiology, and End Results database provides an estimation of incidence of ~0.72 per million cases per year, which results in 0.2% of all cancer deaths in the United States[4]. The median age of diagnosis is in the fifth to sixth decade, with the
Departments ofªSurgery, bSurgery (Breast, Endocrine and General Surgery),
cPathology and dInternal Medicine (Medical Oncology), B.P. Koirala Institute of Health Sciences, Dharan, Nepal
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
*Corresponding author. Address: B.P. Koirala Institute of Health Sciences, Dharan 56700, Nepal. Tel: +977-9842082401, E-mail address: kdkadrsarada@gmail.com (S. Khadka).
Copyright @ 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Annals of Medicine & Surgery (2023) 85:1834-1838
Received 23 September 2022; Accepted 20 December 2022 Published online 27 March 2023 http://dx.doi.org/10.1097/MS9.0000000000000097
HIGHLIGHTS
· Primary adrenocortical carcinoma is a rare entity.
· To accurately diagnose the condition and give the patient a fair prognosis, a multidisciplinary approach involving endocrine surgeons, oncologists, radiologists, and inter- nists is advised.
· Proper genetic counseling is recommended.
· It is critical to know whether the adrenal mass is malignant or not which can be ascertained by computed tomography findings and biopsy.
· Metastasis and a large tumor size confer a poor prognosis.
German ACC Registry recommending a median age of 46 years at diagnosis[5]. There is a predilection for the female gender (the ratio of female to male ranges from 1.5 to 2.5 : 1) in adults[6,71. Despite the high probability of recurrence, complete surgical resection of the tumor can provide the best chance for cure[8]. Due to the limited size of the clinical trials and the lack of data from prospective randomized trials, the chemotherapeutic regimen for recurred or metastatic ACC has not been standardized yet191.
Herein, we present a case of advanced ACC presenting with edema and cytotoxic chemotherapy-induced partial response. This case report is reported according to SCARE guideline[10].
Case report
A 28-year-old man who had no prior history of systemic hyper- tension or diabetes mellitus presented with bilateral limb swelling for 2 months and facial puffiness for 1 month. The swelling was of the pitting type, which started from the feet and eventually spread
1.25sp
up to the knee, aggravating on standing and relieved on lying down. On examination, patient was alert with a sitting blood pressure of 190/120 mm Hg. The patient was treated in the line of hypertensive urgency with tablets of amlodipine 5 mg and losartan 50 mg. Adequate blood pressure control was not obtained and thus patient was admitted in ward and screening for secondary cause of systemic hypertension was carried out . On admission, blood pressure readings were 170/100 mm Hg when supine and 180/100 mm Hg while seated.
On investigation, hypokalaemia was found and treated with oral potassium replacement. A computed tomography (CT) scan of the abdomen and pelvis showed a 7.4×7×6.9 cm mass in the left adrenal gland with increased heterogeneity (Fig. 1). There was evidence of hepatic metastasis as shown in Figures 2A and B. Figure 3 showed long segment circumferential symmetrical enhan- cing thickening (7 mm) of wall of jejunum - likely inflammatory/ ischemic pathology with positive fecal sign with mild dilatation (2.6 cm) - suggestive of small bowel obstruction. To rule out phaeochromocytoma, 24-h urine collection of vanillylmandelic acid
and metanephrine levels was done which were negative. He had facial puffiness and plethora along with central obesity which was of recent suggestive of cortisol excess along with increased libido and gynecomastia (Fig. 4). Figure 5A-C) shows the histopatholo- gical findings. On hormonal work-up, basal cortisol was raised and overnight dexamethasone suppression test was not suppressed along with suppressed morning adrenocorticotropic hormone level suggestive of adrenal cushing. Dehydroepiandrosterone sulphate (DHEAS> 1500), was also raised. As urinary metanephrines were negative and with strong clinical suspicion of ACC, we did Fine needle aspiration cytology of hepatic space occupying lesion which proved to be metastasis from an adrenocortical tumor. On slit lamp examination, no evidence of hypertensive retinopathy was seen. Since an adrenal tumor along with distant metastasis was present, it was attributed to stage IV according to McFarlane staging. Anatomopathological diagnosis was made by percutaneous biopsy of the liver metastasis and histopathology.
The patient was started on chemotherapy with Mitotane (tablet, 500 µg). After 2 days, the patient started deteriorating, and he was started on injectable chemotherapy (injection Doxorubicin 40 mg, Etoposide 100 mg, Cisplatin 40 mg, and tablet Mitiotane 500 mg) which was well tolerated by the patient. The patient’s situation further deteriorated, and he was contacted for the rest of the cycles of chemotherapy until he succumbed to death due to financial constraints.
Discussion
Adrenocortical carcinoma is apparently more common in children[11]. In the adult population, the proportion of secondary malignancies is about 10-20%[11]. However, no association or specific tumor pattern has been mentioned in previous studies. patients, A contralateral tumor is present, presenting either as a synchronous or a metachronous ACC in roughly 2-10% of ACC[11]. Similar to findings in a review by Else and colleagues, our patient had unilateral involvement with the normal contralateral adrenal gland. Moreover, female predilection was reported in previous studies, but in our case, the patient was a male[5,6].
Three main clinical scenarios have been described for ACC patients who present. For 40-60% of patients, the major presenting complaints are symptoms and signs of hormone excess[3,12]. Other third present with nonspecific symptoms such
A
B
25sp
25sp
P 107
1.25sp
as abdominal or flank pain, abdominal fullness, or early satiety due to local tumor growth[11]. Roughly, 20-30% of ACCs are incidental diagnoses by imaging procedures[11]. Only a few patients with ACC present with classical tumor symptoms, such as cachexia or night sweats[3,11]. Paraneoplastic syndromes are rare[12]. The patient presented with symptoms and signs of hor- mone excess, like worsened hypertension. There were no com- pressive symptoms due to local tumors and no paraneoplastic symptoms were present.
Although earlier studies found 49% of patients with metastatic disease at presentation, at present, it is reported that only 25-30% of patients present with metastatic disease[11]. The patient presented with metastatic disease in spite of increased use of abdominal imaging procedures. It may be attributed to the lower availability of imaging procedures in remote areas of Nepal.
On clinical presentation, ACCs are typically large tumors, often measuring more than 6 cm in diameter[13]. Due to the presence of internal hemorrhage, necrosis, and calcifications, these tumors tend to differ in appearance with frequent hetero- geneous enhancement. They are bilateral in 2-10% of cases[12]. Metastases to the liver, lungs, or lymph nodes can be seen. Invasion of adjacent organs or venous extension into the renal vein and/or inferior vena cava may be evident. Contrast- enhanced CT or MRI is the diagnostic imaging modality of choice and is also useful for initial imaging and staging as well as for follow-up. Both modalities are appropriate for detecting local recurrence and metastatic disease[14]. The patient presented with a unilateral tumor of large size (7.4×7×7.9 cm) with hepatic metastases as evident in contrast-enhanced CT.
The diagnosis of ACC is often clear in the setting of a large adrenal mass with concomitant hormone excess. However, if an incidental large adrenal mass is discovered or hormone excess is established, differential diagnosis should be considered if imaging has not been conducted. The main differential diagnoses for ACC are Adrenocorticotropic hormone-independent macronodular hyperplasia and cortisol-producing adenomas, which are differ- entiated by imaging[11]. The main differential diagnoses for an adrenal lesion greater than 4 cm include a large ACA, myeloli- poma, adrenal metastasis of another cancer, pheochromocytoma, adrenal cyst, ganglioneuroma, or other rare tumors of the adrenal gland, such as sarcomas or lymphomas[11]. In our patient, ACC was diagnosed owing to the CT findings (large adrenal mass, increased heterogeneity, irregular borders) with concomitant secondary hypertension and hyperandrogenism.
At present, the only curative approach to ACC is complete tumor resection. Adjuvant therapies are targeted to decrease the chance of recurrence. All therapy for unresectable or metastatic ACC must be considered palliative. This needs to be discussed with the patient so that reasonable expectations are set[11]. Our patient presented in stage IV with hepatic metastasis, so even though, adrenalectomy was initially planned, it was not per- formed owing to its large size, distant metastasis, and uncon- trolled hypertension.
The outcomes have remained suboptimal after surgical resec- tion alone[11]. Evidence suggests that patients with ACC remain at high risk for tumor recurrence despite complete surgical tumor excision, which has warranted the search for adjuvant therapies. Adjuvant treatment is routinely started within 3 months after surgery. A recent large retrospective study indicates a benefit of adjuvant mitotane therapy[11]. Cytotoxic chemotherapy is cur- rently the standard treatment for advanced and metastasized ACC. Initial studies in the 1970s and 1980s evaluated single- compound regimens with minor success, showing response rates ranging from 10 to 20%[11]. A recent phase 3 trial (FIRM-ACT, First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment) compared the most promising regimens [etoposide, doxorubicin, cislatin, and mitotane (EDPM) vs. streptozotocin, mitotane] to establish a gold standard of cytotoxic chemotherapy for ACC. This study sup- ported the efficacy of chemotherapy and proved the superiority of EDPM[11]. Thus, we opted to provide an EDPM regimen to our patient, but it only showed a partial response.
Naturally, age at diagnosis is correlated with decreased overall survival in patients with ACC[15]. Tumor characteristics of malignancy and the velocity of tumor growth are usually related to a poor prognosis. Tumor extent (e.g. stage), specifically the
A
B
C
presence of distant metastasis and the number of organs involved in metastatic disease, is a bad prognostic factor[16]. High tumor grade (> 20 mitoses per high-power field), on the other hand, is also an unfavorable prognostic factor[11]. Since ACC was diag- nosed at a later stage, the velocity of growth could not be ascer- tained. The presence of distant metastases and their large size proved to be unfavorable prognostic factors.
Conclusions
Adrenocortical carcinoma is an extremely uncommon tumor of the adrenal gland, and it is even more uncommon when it man- ifests without any symptoms. If patients exhibit signs of rapid and multiple adrenocortical hormone excess, such as weakness, hypokalaemia, or hypertension, ACC may be suspected. Recently developed gynecomastia in men may be brought on by an ACC producing too much sex hormone. To accurately diagnose the condition and give the patient a fair prognosis, a multi- disciplinary approach involving endocrine surgeons, oncologists, radiologists, and internists is advised. Proper genetic counseling is recommended. It is critical to know whether the adrenal mass is malignant or not and to get this ascertained by a CT finding and biopsy.
Ethical approval
Not required.
Consent
Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor- in-Chief of this journal on request.
Sources of funding
None.
Author contribution
D.N., S.K., P.U., S.K.S., U.K.S .: study concept, data collection, and surgical therapy for the patient. D.N., S.K., S.P.S., S.K.S.,
U.K.S .: writing - original draft preparation. D.N., S.K., S.D., S.K. S., U.K.S .: editing and writing. D.N., S.K., S.K.S .: senior author and manuscript reviewer. All the authors read and approved the final manuscript.
Conflicts of interest disclosure
None.
Research registration unique identifying number (UIN)
None.
Guarantor
Sarada Khadka.
Provenance and peer review
Not commissioned, externally peer-reviewed.
Acknowledgments
None.
References
[1] Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-40.
[2] Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of rando- mized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
[3] Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clin- ical update. J Clin Endocrinol Metab 2006;91:2027-37.
[4] Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30:872-8.
[5] Fassnacht M, Allolio B. Clinical management of adrenocortical carci- noma. Best Pract Res Clin Endocrinol Metab 2009;23:273-89.
[6] Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.
[7] Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004;22:838-45.
[8] Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-50.
[9] van Ditzhuijsen CI, van de Weijer R, Haak HR. Adrenocorticalcarcinoma. Neth J Med 2007;65:55-60.
[10] Agha RA, Franchi T, Sohrabi C, et al. for the SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg 2020;84:226-30.
[11] Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev 2014;35:282-326.
[12] Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with mul- tidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics 2009;29:1333-51.
[13] Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115:243-50.
[14] 98. Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. Am J Roentgenol 2011;196: W706-14.
[15] Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011;80: 1477-84.
[16] Assié G, Antoni G, Tissier F, et al. Prognostic parameters of meta- static adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92: 148-54.